Loading clinical trials...
Loading clinical trials...
A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA
Conditions
Interventions
PF-06741086
PF-06741086
+2 more
Locations
10
United States
UC Denver Hemophilia and Thrombosis Center - Pharmacy
Aurora, Colorado, United States
UC Denver Hemophilia and Thrombosis Center
Aurora, Colorado, United States
Pharmacy
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
Hospital Dr. Sotero del Rio
Santiago, Chile
Klinicki bolnicki centar Zagreb
Zagreb, Croatia
Start Date
March 8, 2017
Primary Completion Date
December 3, 2018
Completion Date
December 3, 2018
Last Updated
December 4, 2019
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions